Bishal Gyawali, Associate Professor at Queen’s University, shared a post on LinkedIn:
“I am asked about my thoughts on SERENA-6 trial in light of yesterday’s FDA ODAC decision. I had put forward my thoughts immediately after ASCO plenary last year in this Medscape video.”
AstraZeneca’s Camizestrant Faces FDA ODAC Review In ESR1-Mutated HR+/HER2− Breast Cancer
